AMR and COVID-19

How can Europe innovate to protect our future?

Thursday, 1 October 2020 | 16:30-18:00 | Room 1

Organised by MSD

Antimicrobial resistance (AMR) is one of the greatest challenges of our age and yet, despite the global discussion around antimicrobial innovation, there has been limited action to address the fundamental economic challenges that have de-incentivised  antimicrobial R&D. Policymakers need to move beyond the traditional approaches to finally “dance with the elephant” – that is, to put in place the necessary market-based reforms that will drive sustainable private investment in antimicrobial R&D.

The COVID-19 pandemic is a wake-up call for health system preparedness and innovation against infectious diseases. It has made clear the huge human and economic costs when we do not have the treatments, vaccines, and diagnostics we need. Further, COVID-19 has highlighted the fundamental role antibiotics play in the treatment of secondary bacterial infections.

Unlike COVID-19, AMR is a predictable and preventable crisis. This timely session will ask:

  • What market reforms are necessary to address the economic barriers to sustainable investment in antimicrobial R&D? How can these support access and appropriate use?
  • What is the role of non-governmental and multi-sector collaborations in driving policy action?
  • What steps should the EU take, e.g. via the forthcoming Pharmaceutical Strategy and the new EU health programme, to enable sustainable investment into the antimicrobial pipeline?


EHFG News & Updates

EHFG Headquarters

EHFG Vienna Office

VAT No. ATU44155007 Bank Data:
IBAN AT 152040400200222240 
Bank Salzburger Sparkasse
Kirchplatz, 5630 Bad Hofgastein, Austria